News

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median ...
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
Pfizer and Arvinas gamble to shift breast cancer treatment paradigm
Breast cancer (BC) is the most prevalent cancer among women globally with two million diagnosed cases each year. Oestrogen ...
Pfizer/Arvinas to seek FDA nod for jointly developed cancer therapy in H2
Pfizer (PFE) and Arvinas (ARVN) aim to seek FDA approval for thier breast cancer therapy vepdegestrant in H2 2025. Read more ...
BioPharma Dive1d
Full Arvinas, Pfizer data confirm potential, limits of ‘Protac’ drug in breast cancer
While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...
The Pharma Letter1d
ASCO: Positive Phase III results for Arvinas and Pfizer's vepdegestrant
Arvinas (Nasdaq: ARVN) and Pfizer (NYSE: PFE) today announced detailed results from the Phase III VERITAC-2 clinical trial ...
Breast cancer: Pfizer-Arvinas drug beats AstraZeneca’s in delaying disease’s progression
New breast cancer drug vepdegestrant shows promising results in increasing survival rates for patients with ESR1 mutations.
Devdiscourse3d
Breakthrough Breast Cancer Treatment by Pfizer and Arvinas Outshines Rival
Clinical trial results reveal an experimental treatment by Pfizer and Arvinas that delays breast cancer progression by over ...
Morningstar4d
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
and NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 VERITAC-2 clinical trial (NCT05654623 ...
Nasdaq3d
Arvinas and Pfizer Announce Phase 3 VERITAC-2 Trial Results Showing Vepdegestrant Improves Progression-Free Survival in ESR1-Mutant Breast Cancer Patients
and NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 VERITAC-2 clinical trial (NCT05654623 ...
Devdiscourse3d
Breakthrough in Breast Cancer Treatment: Pfizer and Arvinas' Promising Results
Pfizer and Arvinas' experimental treatment significantly extends progression-free survival in breast cancer patients with ...